GWPH - 2 Excessive Dips Provide A Very Good Buying Opportunity: GW Pharmaceuticals
GW Pharmaceuticals (GWPH), a biopharmaceutical company that makes its money selling Epidiolex (cannabidiol) for seizures associated with select diseases, is currently down over 55% from highs in May 2019. While the market-wide sell-off due to coronavirus accounts for the latter part of that drop, the sell-off in the pot stock space prior to that accounts for the first part of the drop. Both these sell-offs seem excessive. GWPH isn't really a pot stock, and coronavirus isn't likely to change the way people manage their seizure disorder (meaning GWPH's Epidiolex will continue to sell).